08:03 AM EDT, 05/15/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) , on Wednesday said it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR), to begin planning for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC).

Activities are underway to finalize the Phase 2/3 master protocol design that will evaluate multiple investigational therapies for the treatment of pancreatic cancer. An intent of the study is to produce registration-enabling data, the company said.

GCAR, a U.S. non-profit, is a sponsor of innovative trials, including master protocols and adaptive platform trials.